RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling

Area of Science:

• Molecular Biology
• Cell Signaling
• Drug Discovery

Background:

• RAF kinase inhibitors modulate the ERK cascade by promoting RAF dimerization.
• This dimerization involves a conserved interface critical for scaffold protein interactions, including Kinase Suppressor of RAS (KSR).

Purpose of the Study:

• To investigate the effect of RAF inhibitors on the interaction between KSR1 and RAF proteins (B-RAF and C-RAF).
• To elucidate the mechanisms and consequences of inhibitor-induced KSR1/RAF complex formation on ERK signaling pathways.

Main Methods:

• Utilized biochemical assays and cell-based experiments to assess protein-protein interactions.
• Investigated the role of drug binding, dimer interface residues, and RAS activation in KSR1/RAF complex formation.

Main Results:

• Most RAF inhibitors induced KSR1 binding to both wild-type and oncogenic B-RAF (including V600E B-RAF), but not C-RAF.
• Inhibitor-induced KSR1/B-RAF interaction is dependent on direct drug binding to B-RAF and conserved dimer interface residues, independent of RAS binding.
• KSR1 competes with C-RAF for inhibitor-induced binding to B-RAF, thereby modulating downstream ERK signaling.

Conclusions:

• RAF inhibitors promote KSR1 binding to B-RAF, a novel interaction influencing ERK pathway regulation.
• The competition between KSR1 and C-RAF for B-RAF binding is a key mechanism by which RAF inhibitors alter signaling outcomes.
• Findings provide new insights into RAF inhibitor mechanisms and potential therapeutic strategies targeting the ERK pathway.